Primary subcutaneous B-cell lymphoma: case report and literature review.

Primary cutaneous B-cell lymphomas are defined as malignant B-cell proliferations presenting with cutaneous involvement alone and no evidence of extracutaneous manifestations when complete staging has been performed. It has been shown that the infiltrate in some cases could involve the underlying subcutaneous tissues, but primary localization in this compartment has been rarely reported. We describe here the case of a 53-year-old woman who noticed a nodular lesion on the left shoulder that rapidly enlarged in a few months.

Recurrent aphthous stomatitis as an expression of pathergy in atopics.

Background: Recurrent Aphthous Stomatitis (RAS) may be part of the "atopic background". Recently it has been reported that aphtous stomatitis could be an expression of atopic diathesis. The aim of this study is to verify whether the prevalence of posttraumatic aphthae is higher in patients with RAS and atopic diathesis than in patients with RAS without atopy.

Knowledge of sexually transmitted diseases and condom use among female street sex workers in Padua.

Objectives: The aim of the present study was to investigate knowledge of sexually transmitted diseases (STDs) and condom use in a population of young female street sex workers from eastern Europe and other non-EU countries based in the Padua area (north-eastern Italy). To assess whether any aspects of their behavior might foster the spread of STDs.

Study Design: Street sex workers (prostitutes) were approached on the streets or during non-STD medical appointments, their knowledge of STDs and condom use were evaluated.

Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma.

Purpose: To evaluate the efficacy and side effects of psolaren with ultraviolet light A (PUVA) and interferon-alpha-2a (IFN-alpha-2a) in patients with mycosis fungoides (MF) and Sézary syndrome (SS).

Patients And Methods: From May 1993 to January 1999, 63 symptomatic patients with all stages of MF and SS were treated in a prospective Phase II trial with systemic escalating doses of IFN-alpha-2a combined with PUVA for 1 year, followed by indefinite PUVA maintenance in complete responding patients.

Results: Sixty-three patients were enrolled (Stage IA, n = 6; IB, n = 37; IIA, n = 3; IIB, n = 3; III, n = 12; IVA, n = 2).